تداخلات بريدنيزون

At the primary analysis, increased incidences of fractures (28.6% vs 11.4%) and deaths (38.5% vs 35.5%) have been observed in patients who received abiraterone acetate plus a corticosteroid in combination with radium Ra 223 dichloride compared to patients who received placebo in combination with abiraterone acetate plus a corticosteroid. (نشرة أبيراتيرون، التحذيرات والاحتياطات)

Coadministration of fluticasone propionate and REYATAZ with ritonavir is not recommended unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects [see Warnings and Precautions (5.1) ] . (نشرة أتازانافير، التداخلات الدوائية)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (نشرة أداليموماب، تحذير مؤطر)

…Antihistamines Thyroid hormones Diuretics Cardiac glycosides, such as digitalis glycosides Quinidine Drugs potentiating hypokalemic effects of epinephrine • Potassium depleting diuretics • Corticosteroids • Theophylline Epinephrine should not be used to counteract circulatory collapse or hypotension caused by phenothiazines, as a reversal of the pressor effects of epinephrine… (نشرة أدرينالين، التداخلات الدوائية)

Use of a LABA, including arformoterol tartrate inhalation solution, without an inhaled corticosteroid is contraindicated in patients with asthma. (نشرة أرفورموتيرول، موانع الاستعمال)

Withhold INLYTA and avelumab or pembrolizumab, initiate corticosteroid therapy as needed, and/or permanently discontinue the combination for severe or life-threatening hepatotoxicity. (نشرة أكسيتينيب، التحذيرات والاحتياطات)

…(5.7) , Drug Interactions (7) , and Clinical Pharmacology (12.3) ]: Anticonvulsants: carbamazepine, oxcarbazepine, phenobarbital, phenytoin Antimycobacterials: rifampin, rifapentine Glucocorticoid (systemic): dexamethasone (more than a single-dose) Herbal Products: St John's wort ( Hypericum perforatum ) Proton Pump Inhibitors: e.g., dexlansoprazole, esomeprazole,… (نشرة إمتريسيتابين وريلبيفيرين وتينوفوفير، موانع الاستعمال)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (نشرة إنفليكسيماب، تحذير مؤطر)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (نشرة أوباداسيتينيب، تحذير مؤطر)

• use of a long-acting beta 2 -adrenergic agonist (LABA), including vilanterol, one of the active ingredients in Umeclidinium and Vilanterol ELLIPTA, without an inhaled corticosteroid (ICS), in patients with asthma [see Warnings and Precautions ( 5.1 )] . (نشرة أوميكليدينيوم وفيلانتيرول، موانع الاستعمال)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (نشرة إيتانرسبت، تحذير مؤطر)

Most patients with rheumatoid arthritis who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (نشرة باريسيتينيب، تحذير مؤطر)

Two of the four cases were life-threatening and resolved without treatment or with medication (corticosteroids). (نشرة تراندولابريل، التحذيرات)

At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (نشرة تريتينوين، تحذير مؤطر)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (نشرة توسيليزوماب، تحذير مؤطر)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (نشرة توفاسيتينيب، تحذير مؤطر)

If differentiation syndrome is suspected, immediately initiate high-dose corticosteroids and hemodynamic monitoring until resolution. (نشرة ثالث أكسيد الزرنيخ، تحذير مؤطر)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (نشرة دوسيتاكسيل، التحذيرات والاحتياطات)

Antimycobacterials Rifampin Rifapentine Glucocorticoid (systemic) Dexamethasone (more than a single-dose treatment) Herbal Products St. (نشرة ريلبيفيرين، موانع الاستعمال)

WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death. (نشرة سالميتيرول، تحذير مؤطر)

Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (نشرة سوماتروبين، التداخلات الدوائية)

In a multicenter clinical study, de novo renal transplant patients treated with sirolimus, mycophenolate mofetil (MMF), steroids, and an IL-2 receptor antagonist had significantly higher acute rejection rates and numerically higher death rates compared to patients treated with cyclosporine, MMF, steroids, and IL-2 receptor antagonist. (نشرة سيروليموس، التحذيرات والاحتياطات)

Use of a LABA, including formoterol fumarate inhalation solution, without an inhaled corticosteroid is contraindicated in patients with asthma [see Warnings and Precautions (5.1) ]. (نشرة فورموتيرول، موانع الاستعمال)

Coadministration of fluticasone and fosamprenavir calcium/ritonavir is not recommended unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects. (نشرة فوسامبرينافير، التداخلات الدوائية)

Fluticasone: Coadministration of fluticasone propionate and ketoconazole is not recommended unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects. (نشرة كيتوكونازول، التداخلات الدوائية)

Moreover, cholesterol and other products of the cholesterol biosynthesis pathway are essential components for fetal development, including synthesis of steroids and cell membranes. (نشرة لوفاستاتين، موانع الاستعمال)

None of the cases were considered life-threatening and all resolved either without treatment or with medication (antihistamines or glucocorticoids). (نشرة موكسيبريل، التحذيرات)

If shock, severe trauma or infection occurs or develops, temporarily discontinue LYSODREN and administer exogenous steroids. (نشرة ميتوتان، تحذير مؤطر)

WARNING: TERMINATION OF PREGNANCY Mifepristone is a potent antagonist of progesterone and cortisol via the progesterone and glucocorticoid (GR-II) receptors, respectively. (نشرة ميفيبريستون، تحذير مؤطر)

Therefore, use of prednisone to prevent nevirapine-associated rash is not recommended. (نشرة نيفيرابين، التحذيرات والاحتياطات)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (نشرة بريدنيزون، التداخلات الدوائية)

Anticoagulant agents: May enhance or diminish anticoagulant effects. (نشرة بريدنيزون، التداخلات الدوائية)

Anticoagulant agents: May enhance or diminish anticoagulant effects. (نشرة بريدنيزون، التداخلات الدوائية)

Patients receiving concomitant anti-angiogenic agents, corticosteroids, NSAIDs, or taxane-based chemotherapy, or who have prior history of peptic ulceration or diverticular disease may be at increased risk of perforation [see Adverse Reactions (6.1 , 6.2) ]. (نشرة إرلوتينيب، التحذيرات والاحتياطات)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (نشرة بريدنيزون، التداخلات الدوائية)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (نشرة بريدنيزون، التداخلات الدوائية)

In a detailed case report, 4 documented lymphopenia, diminished IgG and IgM levels, CMV infection, and a decreased thymic shadow were noted in an infant born to a mother receiving 150 mg azathioprine and 30 mg prednisone daily throughout pregnancy. (نشرة أزاثيوبرين، التحذيرات)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (نشرة بريدنيزون، التداخلات الدوائية)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (نشرة بريدنيزون، التداخلات الدوائية)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (نشرة بريدنيزون، التداخلات الدوائية)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (نشرة بريدنيزون، التداخلات الدوائية)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (نشرة بريدنيزون، التداخلات الدوائية)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (نشرة بريدنيزون، التداخلات الدوائية)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (نشرة بريدنيزون، التداخلات الدوائية)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (نشرة بريدنيزون، التداخلات الدوائية)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (نشرة بريدنيزون، التداخلات الدوائية)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (نشرة بريدنيزون، التداخلات الدوائية)

Patients receiving concomitant corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs) or anti-angiogenic agents, or patients with increasing age or who have an underlying history of gastrointestinal ulceration, underlying diverticular disease or bowel metastases may be at increased risk of perforation. (نشرة أفاتينيب، التحذيرات والاحتياطات)

Antidiabetic agents: May increase blood glucose concentrations. (نشرة بريدنيزون، التداخلات الدوائية)

Antidiabetic agents: May increase blood glucose concentrations. (نشرة بريدنيزون، التداخلات الدوائية)

Sympathomimetics, Methylxanthines, Steroids In clinical studies, concurrent administration of aclidinium bromide and other drugs commonly used in the treatment of COPD including sympathomimetics (short-acting beta 2 agonists), methylxanthines, and oral and inhaled steroids showed no increases in adverse drug reactions. (نشرة أكليدينيوم، التداخلات الدوائية)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة البلادونا والأفيون، التحذيرات والاحتياطات)

If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (نشرة ألبيليسيب، التحذيرات والاحتياطات)

Risk of Neurologic Symptoms: Neurocysticercosis patients may experience cerebral hypertensive episodes, seizures or focal neurologic deficits after initiation of therapy; begin appropriate steroid and anticonvulsant therapy. (نشرة ألبيندازول، التحذيرات والاحتياطات)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (نشرة بريدنيزون، التداخلات الدوائية)

Antidiabetic agents: May increase blood glucose concentrations. (نشرة بريدنيزون، التداخلات الدوائية)

Antidiabetic agents: May increase blood glucose concentrations. (نشرة بريدنيزون، التداخلات الدوائية)

Patients who experience these effects, even without respiratory distress, require prolonged observation and appropriate monitoring measures since treatment with antihistamines and corticosteroids may not be sufficient to prevent respiratory involvement. (نشرة أليسكيرين، التحذيرات والاحتياطات)

Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (نشرة إليكساكافتور وتيزاكافتور وإيفاكافتور، التحذيرات والاحتياطات)

Institute appropriate medical management (e.g., glucocorticoids, epinephrine, meperidine) for infusion-related reactions as needed [see Dosage and Administration (2.2) ] . (نشرة أليمتوزوماب، التحذيرات والاحتياطات)

…osteonecrosis of the jaw include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting… (نشرة أليندرونات، التحذيرات والاحتياطات)

Antidiabetic agents: May increase blood glucose concentrations. (نشرة بريدنيزون، التداخلات الدوائية)

Antidiabetic agents: May increase blood glucose concentrations. (نشرة بريدنيزون، التداخلات الدوائية)

Corticosteroids and Corticotropin (ACTH) Concurrent use of corticosteroids and ACTH may potentiate hypokalemia, which could predispose the patient to cardiac dysfunction. (نشرة أمفوتيريسين ب، التداخلات الدوائية)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (نشرة بريدنيزون، التداخلات الدوائية)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (نشرة بريدنيزون، التداخلات الدوائية)

Antidiabetic agents: May increase blood glucose concentrations. (نشرة بريدنيزون، التداخلات الدوائية)

Antidiabetic agents: May increase blood glucose concentrations. (نشرة بريدنيزون، التداخلات الدوائية)

Antidiabetic agents: May increase blood glucose concentrations. (نشرة بريدنيزون، التداخلات الدوائية)

Antidiabetic agents: May increase blood glucose concentrations. (نشرة بريدنيزون، التداخلات الدوائية)

Antidiabetic agents: May increase blood glucose concentrations. (نشرة بريدنيزون، التداخلات الدوائية)

Antidiabetic agents: May increase blood glucose concentrations. (نشرة بريدنيزون، التداخلات الدوائية)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (نشرة بريدنيزون، التداخلات الدوائية)

The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in those taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (نشرة أوفلوكساسين، التحذيرات)

In multiple sclerosis (MS) clinical trials, all adult and pediatric patients who were treated with OCREVUS received premedication with methylprednisolone (or an equivalent steroid), and may have also received an antihistamine (all pediatric patients) and/or an analgesic/antipyretic to reduce the risk of infusion reactions prior to each infusion. (نشرة أوكريليزوماب، التحذيرات والاحتياطات)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (نشرة بريدنيزون، التداخلات الدوائية)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (نشرة بريدنيزون، التداخلات الدوائية)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة أوكسيكودون، التحذيرات والاحتياطات)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة أوكسيكودون وباراسيتامول، التحذيرات والاحتياطات)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة أوكسيمورفون، التحذيرات والاحتياطات)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة أوليسيريدين، التحذيرات والاحتياطات)

Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (نشرة أوماليزوماب، التحذيرات والاحتياطات)

…osteonecrosis of the jaw include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting… (نشرة إيباندرونات، التحذيرات والاحتياطات)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (نشرة بريدنيزون، التداخلات الدوائية)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (نشرة بريدنيزون، التداخلات الدوائية)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (نشرة بريدنيزون، التداخلات الدوائية)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (نشرة بريدنيزون، التداخلات الدوائية)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (نشرة بريدنيزون، التداخلات الدوائية)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (نشرة بريدنيزون، التداخلات الدوائية)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (نشرة بريدنيزون، التداخلات الدوائية)

Anticoagulant agents: May enhance or diminish anticoagulant effects. (نشرة بريدنيزون، التداخلات الدوائية)

Antitubercular Drugs Serum concentrations of isoniazid may be decreased. (نشرة بريدنيزون، التداخلات الدوائية)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (نشرة بريدنيزون، التداخلات الدوائية)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (نشرة بريدنيزون، التداخلات الدوائية)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (نشرة بريدنيزون، التداخلات الدوائية)

Oral hydration, recumbency, intravenous normal saline, and/or parenteral corticosteroids have been used to treat postural hypotension. (نشرة إيفرمكتين، التحذيرات)

CYP 3A4 Inducers (e.g., Barbiturates, Phenytoin, Carbamazepine, and Rifampin) Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. (نشرة بريدنيزون، التداخلات الدوائية)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (نشرة بريدنيزون، التداخلات الدوائية)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (نشرة بريدنيزون، التداخلات الدوائية)

Anticoagulant agents: May enhance or diminish anticoagulant effects. (نشرة بريدنيزون، التداخلات الدوائية)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (نشرة بريدنيزون، التداخلات الدوائية)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة باراسيتامول وكودايين، التحذيرات)

If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (نشرة باسيريوتيد، التحذيرات والاحتياطات)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (نشرة بريدنيزون، التداخلات الدوائية)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (نشرة بريدنيزون، التداخلات الدوائية)

Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (نشرة باميدرونات، التحذيرات والاحتياطات)

The following appear to be major risk factors for the development of these events: decreased oxygen delivery to tissues; serious neurological injury and/or sepsis; high dosages of one or more of the following pharmacological agents: vasoconstrictors, steroids, inotropes and/or prolonged, high-dose infusions of propofol (> 5 mg/kg/hour for > 48 hours). (نشرة بروبوفول، التحذيرات والاحتياطات)

Changes in thyroid status of the patient may necessitate adjustment in dosage. (نشرة بريدنيزون، التحذيرات والاحتياطات)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (نشرة بريدنيزون، التداخلات الدوائية)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة بروميثازين وكودايين، التحذيرات والاحتياطات)

Published animal studies show prednisolone to be teratogenic in rats, rabbits, hamsters, and mice with increased incidence of cleft palate in offspring. (نشرة بريدنيزون، التحذيرات والاحتياطات)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (نشرة بريدنيزون، التداخلات الدوائية)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة بنتازوسين ونالوكسون، التحذيرات)

• Reduction in Corticosteroid Dosage: Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with FASENRA. (نشرة بنراليزوماب، التحذيرات والاحتياطات)

Treatment has consisted of high doses of corticosteroids alone or, in some cases, concomitantly with an immunosuppressant. (نشرة بنسيلامين، التحذيرات)

…risk of seizure: concomitant use of other medications that lower the seizure threshold (e.g., other bupropion products, antipsychotics, tricyclic antidepressants, theophylline, and systemic corticosteroids), metabolic disorders (e.g., hypoglycemia, hyponatremia, severe hepatic impairment, and hypoxia), or use of illicit drugs (e.g., cocaine) or abuse or misuse… (نشرة بوبروبيون، التحذيرات والاحتياطات)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة بوبرينورفين، التحذيرات والاحتياطات)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة بوبرينورفين ونالوكسون، التحذيرات والاحتياطات)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (نشرة بريدنيزون، التداخلات الدوائية)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (نشرة بريدنيزون، التداخلات الدوائية)

CYP 3A4 Inducers (e.g., Barbiturates, Phenytoin, Carbamazepine, and Rifampin) Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. (نشرة بريدنيزون، التداخلات الدوائية)

CYP 3A4 Inducers (e.g., Barbiturates, Phenytoin, Carbamazepine, and Rifampin) Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. (نشرة بريدنيزون، التداخلات الدوائية)

CYP 3A4 Inducers (e.g., Barbiturates, Phenytoin, Carbamazepine, and Rifampin) Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. (نشرة بريدنيزون، التداخلات الدوائية)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة بوتورفانول، التحذيرات)

Prednisone reduction can be accomplished by reducing the daily prednisone dose by 2.5 mg on a weekly basis during therapy with PULMICORT FLEXHALER. (نشرة بوديزونيد، التحذيرات والاحتياطات)

Prednisone reduction can be accomplished by reducing the daily prednisone dose by 2.5 mg on a weekly basis during therapy with budesonide and formoterol fumarate dihydrate. (نشرة بوديزونيد وفورموتيرول، التحذيرات والاحتياطات)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (نشرة بريدنيزون، التداخلات الدوائية)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (نشرة بريدنيزون، التداخلات الدوائية)

Prior and Concomitant Treatment with Anti-neoplastic, Immune-Modulating, or Immunosuppressive Therapies Anti-neoplastic, immune-modulating, or immunosuppressive therapies (including corticosteroids) should be coadministered with caution because of the risk of additive immune system effects [see Drug Interactions (7.1) ] . (نشرة بونيسيمود، التحذيرات والاحتياطات)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة بيثيدين، التحذيرات والاحتياطات)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (نشرة بريدنيزون، التداخلات الدوائية)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (نشرة بريدنيزون، التداخلات الدوائية)

Anticoagulant agents: May enhance or diminish anticoagulant effects. (نشرة بريدنيزون، التداخلات الدوائية)

Corticosteroids (systemic): cortisone/hydrocortisone dexamethasone ↑ corticosteroids (systemic) ↓ lenacapavir (dexamethasone) Concomitant administration with systemic corticosteroids whose exposures are significantly increased by CYP3A inhibitors can increase the risk for Cushing's syndrome and adrenal suppression. (نشرة بيكتيغرافير وإمتريسيتابين وتينوفوفير ألافيناميد، التداخلات الدوائية)

Antidiabetic agents: May increase blood glucose concentrations. (نشرة بريدنيزون، التداخلات الدوائية)

Hypercorticism and Adrenal Suppression QVAR REDIHALER will often help control asthma symptoms with less suppression of HPA function than therapeutically equivalent oral doses of prednisone. (نشرة بيكلوميثازون، التحذيرات والاحتياطات)

Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (نشرة بينداموستين، التحذيرات والاحتياطات)

Antidiabetic agents: May increase blood glucose concentrations. (نشرة بريدنيزون، التداخلات الدوائية)

Antidiabetic agents: May increase blood glucose concentrations. (نشرة بريدنيزون، التداخلات الدوائية)

Antidiabetic agents: May increase blood glucose concentrations. (نشرة بريدنيزون، التداخلات الدوائية)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة تابنتادول، التحذيرات والاحتياطات)

Mild or Moderate CYP3A Inducers Methylprednisolone, prednisone May decrease tacrolimus whole blood trough concentrations. (نشرة تاكروليموس، التداخلات الدوائية)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (نشرة بريدنيزون، التداخلات الدوائية)

Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (نشرة تراستوزوماب، التحذيرات والاحتياطات)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة ترامادول، التحذيرات والاحتياطات)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة ترامادول وباراسيتامول، التحذيرات والاحتياطات)

Other Considerations Concurrent use of hydrochlorothiazide with amphotericin B or corticosteroids or corticotropin (ACTH) may intensify electrolyte imbalance, particularly hypokalemia, although the presence of triamterene minimizes the hypokalemic effect. (نشرة تريامتيرين وهيدروكلوروثيازيد، التداخلات الدوائية)

Abuse of Testosterone and Monitoring of Serum Testosterone : If testosterone use at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids is suspected, check serum testosterone concentration ( 5.5 ). (نشرة تستوستيرون، التحذيرات والاحتياطات)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (نشرة بريدنيزون، التداخلات الدوائية)

Corticosteroids and ACTH: Increased risk of hypokalemia. (نشرة توراسيميد، التداخلات الدوائية)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (نشرة بريدنيزون، التداخلات الدوائية)

If the patient needs more doses of terbutaline sulfate tablets than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and the treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. (نشرة تيربوتالين، التحذيرات)

Antidiabetic agents: May increase blood glucose concentrations. (نشرة بريدنيزون، التداخلات الدوائية)

Changes in thyroid status of the patient may necessitate adjustment in dosage. (نشرة بريدنيزون، التحذيرات والاحتياطات)

Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (نشرة تيساموريلين، التداخلات الدوائية)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (نشرة بريدنيزون، التداخلات الدوائية)

If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (نشرة تيمسيروليموس، التحذيرات والاحتياطات)

Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (نشرة تيموزولوميد، التحذيرات والاحتياطات)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (نشرة تيوتروبيوم، التداخلات الدوائية)

Dosage Increases: Increases in the dose of theophylline should not be made in response to an acute exacerbation of symptoms of chronic lung disease since theophylline provides little added benefit to inhaled beta2 -selective agonists and systemically administered corticosteroids in this circumstance and increases the risk of adverse effects. (نشرة ثيوفيلين، التحذيرات)

A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with a history of concomitant risk factors (e.g., cancer, chemotherapy, angiogenesis inhibitors, radiotherapy, corticosteroids, poor oral hygiene, preexisting dental disease or infection, anemia, coagulopathy). (نشرة حمض الزوليدرونيك، التحذيرات والاحتياطات)

Oral Contraceptive Steroids Administration of a single-dose of ethinyloestradiol (50 mcg)/levonorgestrel (250 mcg) to 6 women on valproate (200 mg BID) therapy for 2 months did not reveal any pharmacokinetic interaction. (نشرة حمض الفالبرويك، التداخلات الدوائية)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (نشرة بريدنيزون، التداخلات الدوائية)

Antidiabetic agents: May increase blood glucose concentrations. (نشرة بريدنيزون، التداخلات الدوائية)

Antidiabetic agents: May increase blood glucose concentrations. (نشرة بريدنيزون، التداخلات الدوائية)

Eosinophilic pneumonia: Discontinue Daptomycin for Injection and consider treatment with systemic steroids. (نشرة دابتومايسين، التحذيرات والاحتياطات)

Anticoagulant agents: May enhance or diminish anticoagulant effects. (نشرة بريدنيزون، التداخلات الدوائية)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (نشرة بريدنيزون، التداخلات الدوائية)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (نشرة بريدنيزون، التداخلات الدوائية)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (نشرة بريدنيزون، التداخلات الدوائية)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (نشرة بريدنيزون، التداخلات الدوائية)

Eosinophilic Conditions: Be alert to vasculitic rash, worsening pulmonary symptoms, cardiac complications, kidney injury and/or neuropathy, especially upon reduction of oral corticosteroids. (نشرة دوبيلوماب، التحذيرات والاحتياطات)

…treated with 6-mercaptopurine (500 mg/m 2 intravenously daily for 5 days per cycle every 2–3 weeks) and doxorubicin hydrochloride (50 mg/m 2 intravenous once per cycle every 2–3 weeks) alone or with vincristine and prednisone, all developed hepatic dysfunction manifested by increased total serum bilirubin, alkaline phosphatase and aspartate aminotransferase. (نشرة دوكسوروبيسين، التداخلات الدوائية)

Antidiabetic agents: May increase blood glucose concentrations. (نشرة بريدنيزون، التداخلات الدوائية)

…following drugs can be coadministered with dolutegravir without a dose adjustment: atazanavir/ritonavir, darunavir/ritonavir, elbasvir/grazoprevir, methadone, midazolam, omeprazole, oral contraceptives containing norgestimate and ethinyl estradiol, prednisone, rifabutin, rilpivirine, sofosbuvir/velpatasvir, and tenofovir [see Clinical Pharmacology ( 12.3 )] . (نشرة دولوتيغرافير، التداخلات الدوائية)

Digitalis Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia. (نشرة بريدنيزون، التداخلات الدوائية)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (نشرة بريدنيزون، التداخلات الدوائية)

Anticholinergic drugs in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as corticosteroids. (نشرة ديسيكلومين، التداخلات الدوائية)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (نشرة بريدنيزون، التداخلات الدوائية)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (نشرة بريدنيزون، التداخلات الدوائية)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (نشرة بريدنيزون، التداخلات الدوائية)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (نشرة بريدنيزون، التداخلات الدوائية)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (نشرة بريدنيزون، التداخلات الدوائية)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (نشرة بريدنيزون، التداخلات الدوائية)

Other risk factors for the development of ONJ include immunosuppressive therapy, treatment with angiogenesis inhibitors, systemic corticosteroids, diabetes, and gingival infections. (نشرة دينوسوماب، التحذيرات والاحتياطات)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (نشرة بريدنيزون، التداخلات الدوائية)

Therefore, for patients receiving both neuromuscular blocking agents (including Rocuronium Bromide Injection) and corticosteroids, the period of use of the neuromuscular blocking agent should be limited as much as possible and only used in the setting where in the opinion of the prescribing physician, the specific advantages of the drug outweigh the risk. (نشرة روكورونيوم، التحذيرات والاحتياطات)

Antidiabetic agents: May increase blood glucose concentrations. (نشرة بريدنيزون، التداخلات الدوائية)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (نشرة بريدنيزون، التداخلات الدوائية)

…the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (نشرة ريزيدرونات، التحذيرات والاحتياطات)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (نشرة بريدنيزون، التداخلات الدوائية)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (نشرة بريدنيزون، التداخلات الدوائية)

Anticoagulant agents: May enhance or diminish anticoagulant effects. (نشرة بريدنيزون، التداخلات الدوائية)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (نشرة بريدنيزون، التداخلات الدوائية)

Prior to the first BIZENGRI infusion, premedicate with a corticosteroid, an H1 antihistamine and acetaminophen to reduce the risk of IRRs [see Dosage and Administration (2.4) ]. (نشرة زينوكوتوزوماب، التحذيرات والاحتياطات)

Antidiabetic agents: May increase blood glucose concentrations. (نشرة بريدنيزون، التداخلات الدوائية)

Antidiabetic agents: May increase blood glucose concentrations. (نشرة بريدنيزون، التداخلات الدوائية)

If the patient needs more doses of Albuterol Sulfate HFA than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. (نشرة سالبوتامول، التحذيرات والاحتياطات)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (نشرة بريدنيزون، التداخلات الدوائية)

The neuromuscular blocking effect of succinylcholine may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase [see Warnings and Precautions (5.9) ]. (نشرة سكسينيل كولين، التداخلات الدوائية)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (نشرة بريدنيزون، التداخلات الدوائية)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (نشرة بريدنيزون، التداخلات الدوائية)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (نشرة بريدنيزون، التداخلات الدوائية)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (نشرة بريدنيزون، التداخلات الدوائية)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (نشرة بريدنيزون، التداخلات الدوائية)

The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (نشرة سيبروفلوكساسين، التحذيرات والاحتياطات)

Drug Interactions Reversible decreases in steady-state plasma digoxin concentrations and renal glycoside excretion were observed in patients receiving beta-acetyldigoxin and chemotherapy regimens containing cyclophosphamide, vincristine and prednisone with or without cytarabine injection or procarbazine. (نشرة سيتارابين، التداخلات الدوائية)

Antidiabetic agents: May increase blood glucose concentrations. (نشرة بريدنيزون، التداخلات الدوائية)

Antidiabetic agents: May increase blood glucose concentrations. (نشرة بريدنيزون، التداخلات الدوائية)

High concentrations of cefoxitin in the urine may interfere with measurement of urinary 17-hydroxy-corticosteroids by the Porter-Silber reaction, and produce false increases of modest degree in the levels reported. (نشرة سيفوكسيتين، التحذيرات والاحتياطات)

Cyclosporine: Increase in activity of both, cyclosporine and corticosteroid when administered concurrently. (نشرة بريدنيزون، التداخلات الدوائية)

Prednisone reduction can be accomplished by reducing the daily prednisone dose by 2.5 mg on a weekly basis during ALVESCO therapy [see Dosage and Administration ( 2 )] . (نشرة سيكليسونيد، التحذيرات والاحتياطات)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (نشرة بريدنيزون، التداخلات الدوائية)

Antidiabetic agents: May increase blood glucose concentrations. (نشرة بريدنيزون، التداخلات الدوائية)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (نشرة بريدنيزون، التداخلات الدوائية)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (نشرة بريدنيزون، التداخلات الدوائية)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (نشرة بريدنيزون، التداخلات الدوائية)

Antidiabetic agents: May increase blood glucose concentrations. (نشرة بريدنيزون، التداخلات الدوائية)

Antidiabetic agents: May increase blood glucose concentrations. (نشرة بريدنيزون، التداخلات الدوائية)

Antidiabetic agents: May increase blood glucose concentrations. (نشرة بريدنيزون، التداخلات الدوائية)

Antidiabetic agents: May increase blood glucose concentrations. (نشرة بريدنيزون، التداخلات الدوائية)

Corticosteroids, valproic acid, or haloperidol : May increase plasma ammonia level; monitor ammonia levels closely. (نشرة غليسرول فينيل بوتيرات، التداخلات الدوائية)

Antidiabetic agents: May increase blood glucose concentrations. (نشرة بريدنيزون، التداخلات الدوائية)

Prednisone reduction can be accomplished by reducing the daily prednisone dose by 2.5 mg on a weekly basis during therapy with Fluticasone Propionate DISKUS. (نشرة فلوتيكازون، التحذيرات والاحتياطات)

Hypercorticism and Adrenal Suppression Fluticasone propionate, a component of Fluticasone Propionate/Salmeterol MDPI, will often help control asthma symptoms with less suppression of HPA function than therapeutically equivalent oral doses of prednisone. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (نشرة بريدنيزون، التداخلات الدوائية)

Use of more than one corticosteroid-containing product at the same time may increase the total systemic absorption of topical corticosteroids. (نشرة فلوسينونيد، التحذيرات والاحتياطات)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (نشرة بريدنيزون، التداخلات الدوائية)

The use of flunisolide with alternate-day prednisone systemic treatment could increase the likelihood of HPA suppression compared to a therapeutic dose of either one alone. (نشرة فلونيسوليد، التحذيرات)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة فنتانيل، التحذيرات والاحتياطات)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (نشرة بريدنيزون، التداخلات الدوائية)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (نشرة بريدنيزون، التداخلات الدوائية)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (نشرة بريدنيزون، التداخلات الدوائية)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (نشرة بريدنيزون، التداخلات الدوائية)

Anticoagulant agents: May enhance or diminish anticoagulant effects. (نشرة بريدنيزون، التداخلات الدوائية)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (نشرة بريدنيزون، التداخلات الدوائية)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (نشرة بريدنيزون، التداخلات الدوائية)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (نشرة بريدنيزون، التداخلات الدوائية)

In both cases, the patients were taking a 1.25 mg dose of fingolimod (higher than the recommended 0.5 mg dose) and had received high-dose corticosteroid therapy to treat suspected MS relapses. (نشرة فينغوليمود، التحذيرات والاحتياطات)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (نشرة بريدنيزون، التداخلات الدوائية)

CYP 3A4 Inducers (e.g., Barbiturates, Phenytoin, Carbamazepine, and Rifampin) Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. (نشرة بريدنيزون، التداخلات الدوائية)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (نشرة بريدنيزون، التداخلات الدوائية)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (نشرة بريدنيزون، التداخلات الدوائية)

Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (نشرة فينيل أسيتات الصوديوم وبنزوات الصوديوم، التداخلات الدوائية)

Valproic Acid, Haloperidol, or Corticosteroids : May increase plasma ammonia level; monitor ammonia levels closely. (نشرة فينيل بوتيرات الصوديوم، التداخلات الدوائية)

Agonistic Effects (increase in BIORPHEN blood pressure effect) can occur with monoamine oxidase inhibitors (MAOI), oxytocin and oxytocic drugs, tricyclic antidepressants, angiotensin and aldosterone, atropine, steroids, norepinephrine transporter inhibitors, ergot alkaloids. (نشرة فينيليفرين، التداخلات الدوائية)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (نشرة بريدنيزون، التداخلات الدوائية)

Antidiabetic agents: May increase blood glucose concentrations. (نشرة بريدنيزون، التداخلات الدوائية)

Prevention or Management Consider a possible decrease in cladribine efficacy if potent BCRP (e.g., corticosteroids) or P-gp (e.g., rifampicin, St. (نشرة كلادريبين، التداخلات الدوائية)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (نشرة بريدنيزون، التداخلات الدوائية)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (نشرة بريدنيزون، التداخلات الدوائية)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة كودايين، التحذيرات والاحتياطات)

Plasma cholinesterase activity may be decreased by chronic administration of certain monoamine oxidase inhibitors, oral contraceptives, glucocorticoids, antimyasthenics (neostigmine), cyclophosphamide, and possibly thiotepa. (نشرة كوكايين، التداخلات الدوائية)

Cholestyramine Cholestyramine may increase the clearance of corticosteroids. (نشرة بريدنيزون، التداخلات الدوائية)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (نشرة بريدنيزون، التداخلات الدوائية)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (نشرة بريدنيزون، التداخلات الدوائية)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (نشرة بريدنيزون، التداخلات الدوائية)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (نشرة بريدنيزون، التداخلات الدوائية)

Antidiabetic agents: May increase blood glucose concentrations. (نشرة بريدنيزون، التداخلات الدوائية)

Even in those instances where swelling of only the tongue is involved, without respiratory distress, patients may require prolonged observation since treatment with antihistamines and corticosteroids may not be sufficient. (نشرة ليزينوبريل وهيدروكلوروثيازيد، التحذيرات)

Changes in thyroid status of the patient may necessitate adjustment in dosage. (نشرة بريدنيزون، التحذيرات والاحتياطات)

Changes in thyroid status of the patient may necessitate adjustment in dosage. (نشرة بريدنيزون، التحذيرات والاحتياطات)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة ليفورفانول، التحذيرات)

If the patient needs more doses of XOPENEX HFA than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. (نشرة ليفوسالبوتامول، التحذيرات والاحتياطات)

The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients usually over 60 years of age, in those taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (نشرة ليفوفلوكساسين، التحذيرات والاحتياطات)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (نشرة بريدنيزون، التداخلات الدوائية)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (نشرة بريدنيزون، التداخلات الدوائية)

Antidiabetic agents: May increase blood glucose concentrations. (نشرة بريدنيزون، التداخلات الدوائية)

Antidiabetic agents: May increase blood glucose concentrations. (نشرة بريدنيزون، التداخلات الدوائية)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (نشرة بريدنيزون، التداخلات الدوائية)

Changes in thyroid status of the patient may necessitate adjustment in dosage. (نشرة بريدنيزون، التحذيرات والاحتياطات)

In patients who experience mild or moderate IRRs, consider premedications, including antihistamines, corticosteroids, and antipyretics. (نشرة مارجيتوكسيماب، التحذيرات والاحتياطات)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (نشرة بريدنيزون، التداخلات الدوائية)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (نشرة بريدنيزون، التداخلات الدوائية)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة مورفين، التحذيرات والاحتياطات)

The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (نشرة موكسيفلوكساسين، التحذيرات والاحتياطات)

Hypercorticism and Adrenal Suppression ASMANEX HFA will often help control asthma symptoms with less suppression of HPA function than therapeutically equivalent oral doses of prednisone. (نشرة موميتازون، التحذيرات والاحتياطات)

Inhaled corticosteroid may be reduced gradually. (نشرة مونتيلوكاست، التحذيرات والاحتياطات)

Decrease corticosteroids gradually, if appropriate. (نشرة ميبوليزوماب، التحذيرات والاحتياطات)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (نشرة بريدنيزون، التداخلات الدوائية)

Antidiabetic agents: May increase blood glucose concentrations. (نشرة بريدنيزون، التداخلات الدوائية)

In a randomized comparative trial of mitoxantrone injection plus low-dose prednisone vs. low-dose prednisone, 7 of 128 patients (5.5 %) treated with mitoxantrone injection had a cardiac event defined as any decrease in LVEF below the normal range, congestive heart failure (n = 3), or myocardial ischemia. (نشرة ميتوكسانترون، التحذيرات)

Corticosteroids Or ACTH May increase the risk of hypokalemia and increase salt and water retention. (نشرة ميتولازون، التداخلات الدوائية)

This can be corrected by giving appropriate doses of corticosteroids. (نشرة ميتيرابون، التحذيرات والاحتياطات)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة ميثادون، التحذيرات والاحتياطات)

Drug Interactions Methazolamide should be used with caution in patients on steroid therapy because of the potential for developing hypokalemia. (نشرة ميثازولاميد، التداخلات الدوائية)

NSAIDs, Aspirin, and Steroids: May elevate and prolong serum methotrexate levels and increase gastrointestinal toxicity. (نشرة ميثوتريكسات، التداخلات الدوائية)

CYP 3A4 Inducers (e.g., Barbiturates, Phenytoin, Carbamazepine, and Rifampin) Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. (نشرة بريدنيزون، التداخلات الدوائية)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (نشرة ميثيل تستوستيرون، التحذيرات)

If not, corticosteroids may be given and other causes of anemia should be considered. (نشرة ميثيل دوبا، التحذيرات)

Changes in thyroid status of the patient may necessitate adjustment in dosage. (نشرة بريدنيزون، التحذيرات والاحتياطات)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (نشرة بريدنيزون، التداخلات الدوائية)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (نشرة بريدنيزون، التداخلات الدوائية)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (نشرة بريدنيزون، التداخلات الدوائية)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (نشرة بريدنيزون، التداخلات الدوائية)

Antidiabetic agents: May increase blood glucose concentrations. (نشرة بريدنيزون، التداخلات الدوائية)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (نشرة بريدنيزون، التداخلات الدوائية)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (نشرة بريدنيزون، التداخلات الدوائية)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (نشرة بريدنيزون، التداخلات الدوائية)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (نشرة بريدنيزون، التداخلات الدوائية)

In Studies MS1 and MS2, an increase in infections was seen in patients concurrently receiving short courses of corticosteroids. (نشرة ناتاليزوماب، التحذيرات والاحتياطات)

Antidiabetic agents: May increase blood glucose concentrations. (نشرة بريدنيزون، التداخلات الدوائية)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (نشرة بريدنيزون، التداخلات الدوائية)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة نالبوفين، التحذيرات)

…hypoglycemia concomitant administration of medications that may lower the seizure threshold, including other bupropion products, antipsychotics, tricyclic antidepressants, theophylline, systemic steroids Recommendations for Reducing the Risk of Seizure: Clinical experience with bupropion suggests that the risk of seizure may be minimized by adhering to the recommended… (نشرة نالتريكسون وبوبروبيون، التحذيرات والاحتياطات)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (نشرة بريدنيزون، التداخلات الدوائية)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (نشرة بريدنيزون، التداخلات الدوائية)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (نشرة بريدنيزون، التداخلات الدوائية)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (نشرة بريدنيزون، التداخلات الدوائية)

Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (نشرة بريدنيزون، التداخلات الدوائية)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (نشرة بريدنيزون، التداخلات الدوائية)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (نشرة بريدنيزون، التداخلات الدوائية)

Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (نشرة نينتيدانيب، التحذيرات والاحتياطات)

Use of more than one corticosteroid-containing product at the same time may increase the total systemic exposure to topical corticosteroids. (نشرة هالوبيتازول، التحذيرات والاحتياطات)

Caution is advised when haloperidol decanoate is used in combination with drugs known to cause electrolyte imbalance (e.g., diuretics or corticosteroids) because hypokalemia, hypomagnesemia, and hypocalcemia are risk factors for QT prolongation. (نشرة هالوبيريدول، التداخلات الدوائية)

Anticoagulant agents: May enhance or diminish anticoagulant effects. (نشرة بريدنيزون، التداخلات الدوائية)

Long-term treatment with steroids may be necessary (see PRECAUTIONS, Laboratory Tests ). (نشرة هيدرالازين، التحذيرات)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة هيدروكودون، التحذيرات والاحتياطات)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (نشرة بريدنيزون، التداخلات الدوائية)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة هيدروكودون وباراسيتامول، التحذيرات)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة هيدروكودون وكلورفينيرامين، التحذيرات والاحتياطات)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة هيدروكودون وهوماتروبين، التحذيرات والاحتياطات)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة هيدرومورفون، التحذيرات والاحتياطات)

Anticoagulant agents: May enhance or diminish anticoagulant effects. (نشرة بريدنيزون، التداخلات الدوائية)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (نشرة إبراتروبيوم، التداخلات الدوائية)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (نشرة بريدنيزون، التداخلات الدوائية)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (نشرة بريدنيزون، التداخلات الدوائية)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (نشرة بريدنيزون، التداخلات الدوائية)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (نشرة بريدنيزون، التداخلات الدوائية)

If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (نشرة ألتيبلاز، التحذيرات والاحتياطات)

OXYGEN, INTRAVENOUS STEROIDS, AND AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS INDICATED. (نشرة أمبيسيلين، التحذيرات)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (نشرة أمفيتامين، التداخلات الدوائية)

Interference with Laboratory Tests Amphetamines can cause a significant elevation in plasma corticosteroid levels. (نشرة أمفيتامين وديكستروأمفيتامين، التداخلات الدوائية)

Most patients with hypersensitivity pneumonitis discontinued treatment with ARIKAYCE and received treatment with corticosteroids [see Adverse Reactions (6.1) ] . (نشرة أميكاسين، التحذيرات والاحتياطات)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (نشرة بريدنيزون، التداخلات الدوائية)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (نشرة بريدنيزون، التداخلات الدوائية)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (نشرة بريدنيزون، التداخلات الدوائية)

Patients improved with discontinuation of therapy and in certain cases administration of corticosteroids. (نشرة أوستيكينوماب، التحذيرات والاحتياطات)

If an allergic reaction occurs, the drug should be discontinued and the patient should receive supportive treatment, e.g. , artificial maintenance of ventilation, pressor amines, antihistamines, and corticosteroids. (نشرة أوكساسيلين، التحذيرات)

Most patients improved promptly with discontinuation of fluoxetine and/or adjunctive treatment with antihistamines or steroids, and all patients experiencing these reactions were reported to recover completely. (نشرة أولانزابين وفلوكسيتين، التحذيرات والاحتياطات)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (نشرة بريدنيزون، التداخلات الدوائية)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (نشرة بريدنيزون، التداخلات الدوائية)

Oxygen, intravenous steroids, and airway management, including intubation, should also be administered as indicated. (نشرة بنسلين G، التحذيرات)

OXYGEN, INTRAVENOUS STEROIDS, AND AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS INDICATED. (نشرة بنسلين V، التحذيرات)

…50,000/μL was required for study eligibility ‡ Data were missing at baseline for one patient In the combination study of bortezomib with rituximab, cyclophosphamide, doxorubicin and prednisone (BR-CAP) in previously untreated mantle cell lymphoma patients, the incidence of thrombocytopenia (≥ Grade 4) was 32% vs 1% for the rituximab, cyclophosphamide, doxorubicin,… (نشرة بورتيزوميب، التحذيرات والاحتياطات)

The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (نشرة بوسلفان، التحذيرات)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (نشرة بريدنيزون، التداخلات الدوائية)

Anticholinesterase Agents Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (نشرة بريدنيزون، التداخلات الدوائية)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (نشرة بريدنيزون، التداخلات الدوائية)

Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (نشرة بيفاسيزوماب، التحذيرات والاحتياطات)

…performed, the following concomitant drugs were used in at least 10% of patients in either or both Sjogren's efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone. (نشرة بيلوكاربين، التداخلات الدوائية)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (نشرة بريدنيزون، التداخلات الدوائية)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (نشرة بريدنيزون، التداخلات الدوائية)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (نشرة توبرامايسين، التداخلات الدوائية)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (نشرة بريدنيزون، التداخلات الدوائية)

If symptoms of hypersensitivity occur, initiate appropriate therapy (e.g., antihistamines, corticosteroids, epinephrine). (نشرة تينيكتيبلاز، التحذيرات والاحتياطات)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (نشرة بريدنيزون، التداخلات الدوائية)

Tendon rupture may occur more frequently in patients over 60 years of age, in those taking corticosteroid or fluoroquinolone drugs, in patients with renal failure, and in patients with previous tendon disorders. (نشرة حمض البيمبيدويك، التحذيرات والاحتياطات)

Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (نشرة داساتينيب، التحذيرات والاحتياطات)

These would include diuretics, laxatives and supraphysiological use of steroid hormones with mineralocorticoid potential. (نشرة دروبيريدول، التداخلات الدوائية)

Anticholinesterase Agents Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (نشرة بريدنيزون، التداخلات الدوائية)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (نشرة ديكستروأمفيتامين، التداخلات الدوائية)

Other Concomitant Medications EVISTA can be concomitantly administered with ampicillin, amoxicillin, antacids, corticosteroids, and digoxin [see Clinical Pharmacology ( 12.3 )] . (نشرة رالوكسيفين، التداخلات الدوائية)

Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (نشرة ريتوكسيماب، التحذيرات والاحتياطات)

Anticholinesterase Agents Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (نشرة بريدنيزون، التداخلات الدوائية)

Most patients improved promptly with adjunctive treatment with antihistamines or steroids and/or upon discontinuation of ziprasidone, and all patients experiencing these reactions were reported to recover completely. (نشرة زيبراسيدون، التحذيرات والاحتياطات)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (نشرة بريدنيزون، التداخلات الدوائية)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (نشرة بريدنيزون، التداخلات الدوائية)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (نشرة سيفادروكسيل، التحذيرات والاحتياطات)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (نشرة سيفاكلور، التحذيرات)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (نشرة سيفبروزيل، التحذيرات)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (نشرة سيفتازيديم، التحذيرات)

Serious acute hypersensitivity reactions may require treatment with epinephrine and other emergency measures including oxygen, corticosteroids, intravenous fluids, intravenous antihistamines, pressor amines, and airway management, as clinically indicated. (نشرة سيفترياكسون، التحذيرات والاحتياطات)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (نشرة سيفدينير، التحذيرات)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (نشرة سيفوتيتان، التحذيرات)

Sixteen (16) drugs tested did not show an in vitro interaction with LOKELMA (allopurinol, apixaban, aspirin, captopril, cyclosporine, digoxin, ethinyl estradiol, lisinopril, magnesium, metformin, phenytoin, prednisone, propranolol, quinapril, spironolactone and ticagrelor). (نشرة سيكلوسيليكات الزركونيوم الصوديوم، التداخلات الدوائية)

Anticholinesterase Agents Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (نشرة بريدنيزون، التداخلات الدوائية)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (نشرة غلوكاغون، التحذيرات والاحتياطات)

TREMFYA was subsequently discontinued, and the liver test abnormalities resolved following administration of corticosteroids [see Adverse Reactions (6.1) ] . (نشرة غوسيلكوماب، التحذيرات والاحتياطات)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (نشرة بريدنيزون، التداخلات الدوائية)

Steroids may or may not be effective in controlling these hemolytic episodes. (نشرة فلودارابين، التحذيرات والاحتياطات)

Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid should be administered concurrently. (نشرة بريدنيزون، التحذيرات والاحتياطات)

Most patients improved promptly with discontinuation of fluoxetine and/or adjunctive treatment with antihistamines or steroids, and all patients experiencing these reactions were reported to recover completely. (نشرة فلوكسيتين، التحذيرات والاحتياطات)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (نشرة بريدنيزون، التداخلات الدوائية)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (نشرة بريدنيزون، التداخلات الدوائية)

الكورتيكوستيرويدات مثل بريدنيزون تقلّل امتصاص الكالسيوم وتخلّ باستقلاب فيتامين د، مما يسهم في فقدان العظم. (NIH Office of Dietary Supplements, Vitamin D)

Anticholinesterase Agents Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (نشرة بريدنيزون، التداخلات الدوائية)

Corticosteroids A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption. (نشرة كالسيتريول، التداخلات الدوائية)

Some subjects in the EPIDIOLEX clinical trials had pruritus, erythema, and angioedema requiring treatment, including corticosteroids and antihistamines. (نشرة كانابيديول (بوصفة طبية)، التحذيرات والاحتياطات)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (نشرة بريدنيزون، التداخلات الدوائية)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (نشرة بريدنيزون، التداخلات الدوائية)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (نشرة بريدنيزون، التداخلات الدوائية)

The use of prophylactic steroids (e.g., 100 mg/m 2 hydrocortisone on Days 1 through 3) may be of benefit in preventing signs or symptoms of SIRS or capillary leak syndrome. (نشرة كلوفارابين، التحذيرات والاحتياطات)

Elevated urinary steroid levels, varying degrees of electrolyte imbalance, hypovolemia, hemoconcentration, and hypoproteinemia may occur. (نشرة كلوميفين، التحذيرات)

The recovery of the adrenal gland may take from days to months so patients should be protected from the stress (e.g., trauma or surgery) by the use of corticosteroids during the period of stress. (نشرة كورتيكوتروبين، التحذيرات والاحتياطات)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (نشرة بريدنيزون، التداخلات الدوائية)

Drug/Laboratory Interactions Quinine may produce an elevated value for urinary 17-ketogenic steroids when the Zimmerman method is used. (نشرة كينين، التداخلات الدوائية)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (نشرة بريدنيزون، التداخلات الدوائية)

Patients with Grade 1 and 2 TFR may also be treated with corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs) and/or narcotic analgesics for management of TFR symptoms. (نشرة ليناليدوميد، التحذيرات والاحتياطات)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (نشرة بريدنيزون، التداخلات الدوائية)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (نشرة ميثامفيتامين، التداخلات الدوائية)

Midodrine hydrochloride has been used in patients concomitantly treated with salt-retaining steroid therapy (i.e., fludrocortisone acetate), with or without salt supplementation. (نشرة ميدودرين، التداخلات الدوائية)

The infusion should be terminated immediately, followed by the administration of volume expanders, pressor agents, corticosteroids, or antihistamines at the discretion of the physician. (نشرة ميلفالان، التحذيرات)

Anticholinesterase Agents Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (نشرة بريدنيزون، التداخلات الدوائية)

Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (نشرة نالتريكسون، التحذيرات والاحتياطات)

Moderate and weak CYP3A4 inducers include, for example: amprenavir, aprepitant, armodafinil, bosentan, efavirnenz, etravirine, Echinacea, modafinil, nafcillin, pioglitazone, prednisone, rufinamide, and vemurafenib. (نشرة نيموديبين، التداخلات الدوائية)

Anticholinesterase Agents Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (نشرة بريدنيزون، التداخلات الدوائية)

Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (نشرة بريدنيزون، التداخلات الدوائية)

Amphotericin B Injection There have been cases reported in which concomitant use of Amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure [see Drug Interactions (7.14) ] . (نشرة بريدنيزون، التداخلات الدوائية)

…influenza vaccine ketoconazole lomefloxacin mebendazole medroxyprogesterone methylprednisolone metronidazole metoprolol nadolol nifedipine nizatidine norfloxacin ofloxacin omeprazole prednisone, prednisolone ranitidine rifabutin roxithromycin sorbitol (purgative doses do not inhibit theophylline absorption) sucralfate terbutaline, systemic terfenadine tetracycline… (نشرة أمينوفيلين، التداخلات الدوائية)

Other Concomitant Drug Therapy Drug-drug interaction studies conducted in healthy subjects between zileuton immediate-release tablets and prednisone and ethinyl estradiol (oral contraceptive), drugs known to be metabolized by the CYP3A4 isoenzyme, have shown no significant interaction. (نشرة زيلوتون، التداخلات الدوائية)